CN1283288C - 一种降脂组合物及其制备方法 - Google Patents
一种降脂组合物及其制备方法 Download PDFInfo
- Publication number
- CN1283288C CN1283288C CN 03108971 CN03108971A CN1283288C CN 1283288 C CN1283288 C CN 1283288C CN 03108971 CN03108971 CN 03108971 CN 03108971 A CN03108971 A CN 03108971A CN 1283288 C CN1283288 C CN 1283288C
- Authority
- CN
- China
- Prior art keywords
- radix
- lipid
- group
- fructus crataegi
- polygoni multiflori
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 83
- 239000003814 drug Substances 0.000 title claims abstract description 40
- 238000000034 method Methods 0.000 title claims description 5
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 150000002632 lipids Chemical class 0.000 claims description 26
- 239000000843 powder Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000002994 raw material Substances 0.000 claims description 8
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 5
- 230000000881 depressing effect Effects 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 239000006228 supernatant Substances 0.000 claims description 5
- 229940126672 traditional medicines Drugs 0.000 claims description 5
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 235000019634 flavors Nutrition 0.000 claims description 4
- 238000005453 pelletization Methods 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 3
- -1 filter Substances 0.000 claims description 2
- 239000000890 drug combination Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 35
- 239000008280 blood Substances 0.000 abstract description 35
- 201000005577 familial hyperlipidemia Diseases 0.000 abstract description 34
- 230000009467 reduction Effects 0.000 abstract description 19
- 230000001737 promoting effect Effects 0.000 abstract description 7
- 230000017531 blood circulation Effects 0.000 abstract description 6
- 210000003734 kidney Anatomy 0.000 abstract description 6
- 210000000952 spleen Anatomy 0.000 abstract description 5
- 230000001603 reducing effect Effects 0.000 abstract description 4
- 238000005728 strengthening Methods 0.000 abstract description 4
- 208000024891 symptom Diseases 0.000 abstract description 3
- 208000004880 Polyuria Diseases 0.000 abstract description 2
- 240000001341 Reynoutria japonica Species 0.000 abstract description 2
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract description 2
- 230000029087 digestion Effects 0.000 abstract description 2
- 230000035619 diuresis Effects 0.000 abstract description 2
- 230000003014 reinforcing effect Effects 0.000 abstract description 2
- 244000233890 Alisma plantago Species 0.000 abstract 1
- 235000017300 Alisma plantago Nutrition 0.000 abstract 1
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- 235000013175 Crataegus laevigata Nutrition 0.000 abstract 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 1
- 241000219780 Pueraria Species 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 230000002787 reinforcement Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 55
- 229940079593 drug Drugs 0.000 description 24
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 24
- YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 21
- 210000002966 serum Anatomy 0.000 description 19
- 241000283973 Oryctolagus cuniculus Species 0.000 description 16
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 238000000465 moulding Methods 0.000 description 13
- 210000002784 stomach Anatomy 0.000 description 13
- 241000272201 Columbiformes Species 0.000 description 10
- 108010023302 HDL Cholesterol Proteins 0.000 description 10
- 229960002297 fenofibrate Drugs 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 150000002338 glycosides Chemical class 0.000 description 8
- 201000001320 Atherosclerosis Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 108010028554 LDL Cholesterol Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 230000002262 irrigation Effects 0.000 description 6
- 238000003973 irrigation Methods 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 238000005303 weighing Methods 0.000 description 6
- DSLZJTNJHMUOTH-UNGPUTHSSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[2-[[(2S)-1-[[(2S)-1-amino-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-carboxy-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]propanoyl]amino]-3-methylbutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoic acid Chemical group CC(C)C[C@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)Cc1cnc[nH]1)C(C)C)[C@@H](C)O)C(=O)N[C@@H](C(C)C)C(N)=O DSLZJTNJHMUOTH-UNGPUTHSSA-N 0.000 description 5
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 241000282894 Sus scrofa domesticus Species 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 229930182470 glycoside Natural products 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 3
- 235000005687 corn oil Nutrition 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000012567 medical material Substances 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 208000035150 Hypercholesterolemia Diseases 0.000 description 2
- HWGBHCRJGXAGEU-UHFFFAOYSA-N Methylthiouracil Chemical compound CC1=CC(=O)NC(=S)N1 HWGBHCRJGXAGEU-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000002481 ethanol extraction Methods 0.000 description 2
- 239000000469 ethanolic extract Substances 0.000 description 2
- 229940058769 fenofibrate 30 mg Drugs 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000037356 lipid metabolism Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 229960002545 methylthiouracil Drugs 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000013547 stew Nutrition 0.000 description 2
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 241000005787 Cistanche Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 240000007711 Peperomia pellucida Species 0.000 description 1
- 101000800134 Rattus norvegicus Thyroglobulin Proteins 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 210000000497 foam cell Anatomy 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000008604 lipoprotein metabolism Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
组别 | 剂量(g/kg) | TG(mmol/L) | TCH(mmol/L) | HDL-ch(mmol/L) |
正常组模型组降脂组合物降脂组合物胶股蓝总甙 | 1.604.800.0234 | 0.7±0.132.14±0.78△△1.26±0.75*0.80±0.311.35±0.43* | 3.23±1.005.34±0.99△△5.22±1.124.27±1.01*4.76±0.81 | 1.52±0.151.44±0.331.68±0.482.13±0.60**1.52±0.27 |
组别 | 剂量(g/kg) | TG(mmol/L) | TCH(mmol/L) | HDL-ch(mmol/L) |
模型组降脂组合物降脂组合物胶股蓝总甙 | 1.083.240.0162 | 1.13±0.33△△0.97±0.130.89±0.19*1.12±0.27 | 5.25±1.593.70±1.13*3.87±0.91*4.09±0.76* | 1.49±0.371.36±0.191.47±0.291.10±0.33 |
组别 | 剂量(g/kg) | TG(mmol/L) | TCH(mmol/L) | HDL-ch(mmol/L) |
模型组降脂组合物降脂组合物胶股蓝总甙 | 1.083.240.0162 | 2.33±0.241.96±0.13**2.10±0.17*2.21±0.36 | 25.0±0.7923.7±1.05*23.0±1.67**23.8±0.84* | 6.18±0.566.02±1.245.77±0.454.05±0.85** |
组别 | 给药前 | 给药后(mmol/L) | |||
2W | 4W | 6W | 8W | ||
IIIIIIIVVVIVIIVIIIIXX | 0.73±0.290.60±0.260.58±0.260.76±0.270.76±0.350.72±0.270.58±0.260.52±0.240.70±0.250.74±0.30 | 0.76±0.421.77±0.591.74±0.661.41±0.411.36±0.422.03±0.781.75±0.561.90±0.761.28±0.581.80±0.59 | 0.73±0.422.30±0.941.75±0.571.36±0.51*1.20±0.50*2.53±0.882.20±0.632.54±0.781.34±0.41*2.28±0.43 | 0.60±0.263.02±1.072.20±0.902.13±0.811.76±0.66*2.67±0.882.56±0.672.48±0.762.11±0.59*2.60±0.74 | 0.59±0.323.76±1.223.08±1.123.10±1.022.80±0.962.95±0.922.62±0.69*2.60±0.57*2.96±0.892.68±0.57* |
组别 | 给药前 | 给药后(mmol/L) | |||
2W | 4W | 6W | 8W | ||
IIIIIIIVVVIVIIVIIIIXX | 1.83±0.541.73±0.742.23±0.612.06±0.531.85±0.572.09±0.631.77±0.491.93±0.611.85±0.662.17±0.72 | 1.72±0.959.55±2.558.07±2.236.62±2.076.18±2.417.68±3.048.74±2.4710.2±3.416.94±2.039.49±3.34 | 1.78±0.8115.6±2.8312.2±3.7212.5±2.20*10.9±2.40*16.4±3.4015.7±2.8615.8±2.8212.0±3.32*16.2±4.52 | 1.95±0.6218.2±4.4115.2±3.1415.5±4.3013.6±4.46*16.6±3.6414.3±3.40*13.4±3.86*13.7±3.77*13.8±3.68* | 1.89±0.6717.8±4.0318.0±4.3416.1±3.8113.7±3.60*14.7±3.6813.6±3.32*12.9±3.98*14.9±3.0012.7±3.77* |
组别 | 给药前 | 给药后(mmol/L) | |||
2W | 4W | 6W | 8W | ||
IIIIIIIVVVIVIIVIIIIXX | 0.80±0.230.75±0.330.99±0.250.87±0.230.80±0.230.92±0.220.78±0.250.80±0.250.75±0.261.04±0.35 | 0.73±0.346.95±1.865.62±1.534.54±1.42**4.09±1.24**5.32±1.816.27±1.857.38±2.234.60±1.55**6.85±2.07 | 0.78±0.3111.8±2.748.96±2.34*9.06±2.14*7.68±1.68**12.3±3.4011.8±2.4111.8±2.638.51±2.19*12.1±3.40 | 0.84±0.3113.7±4.3511.5±3.3811.4±3.029.89±2.59*12.5±2.9510.5±2.779.68±2.69*9.88±2.69*9.94±2.81* | 0.83±0.2613.4±3.1913.7±4.2812.1±3.389.99±2.32*10.9±2.879.81±2.88*9.13±2.68*10.8±2.628.93±2.84** |
组别 | 给药前 | 给药后(mmol/L) | |||
2W | 4W | 6W | 8W | ||
IIIIIIIVVVIVIIVIIIIXX | 0.20±0.060.19±0.080.25±0.060.22±0.060.20±0.100.23±0.060.20±0.060.20±0.080.19±0.060.26±0.09 | 0.18±0.081.73±0.471.41±0.381.14±0.361.02±0.31**1.33±0.451.57±0.461.85±0.561.15±0.391.71±0.52 | 0.19±0.082.94±0.692.24±0.582.27±0.541.92±0.42**3.08±0.852.95±0.602.94±0.662.31±0.55**3.02±0.85 | 0.21±0.083.43±1.092.85±0.852.88±0.762.47±0.65**3.13±0.742.63±0.692.42±0.672.47±0.672.49±0.70 | 0.21±0.063.34±0.803.42±1.073.02±0.852.50±0.582.72±0.722.45±0.722.28±0.672.71±0.662.23±0.71 |
组别 | 给药前 | 给药后(mmol/L) | |||
2W | 4W | 6W | 8W | ||
IIIIIIIVVVIVIIVIIIIXX | 0.83±0.210.79±0.350.98±0.230.97±0.270.85±0.340.95±0.170.79±0.280.93±0.280.91±0.280.87±0.30 | 0.81±0.300.89±0.241.04±0.280.95±0.291.07±0.231.04±0.300.90±0.280.97±0.261.17±0.440.92±0.23 | 0.77±0.250.90±0.261.04±0.231.17±0.351.33±0.29*1.01±0.350.96±0.271.10±0.301.36±0.32*1.08±0.31 | 0.90±0.381.03±0.400.89±0.341.09±0.271.25±0.250.96±0.241.18±0.291.30±0.351.34±0.361.36±0.41 | 0.85±0.221.10±0.280.90±0.351.00±0.321.21±0.241.13±0.311.34±0.461.49±0.42*1.37±0.391.54±0.52* |
组别 | 给药前 | 给药后(mmol/L) | |||
2W | 4W | 6W | 8W | ||
IIIIIIIVVVIVIIVIIIIXX | 2.21±0.612.18±0.952.26±0.572.13±0.572.17±0.762.21±0.532.44±0.702.08±0.642.03±0.682.49±0.84 | 2.12±0.9810.8±2.907.76±2.117.01±2.19*5.78±1.75**7.42±2.539.71±2.8610.5±3.185.83±1.96*10.3±3.12 | 2.33±0.9417.4±4.0411.8±3.07**10.7±2.52**8.22±1.80**16.3±4.4916.4±3.3414.4±3.228.81±2.26**15.0±4.21 | 2.17±0.6917.6±5.5917.1±5.0614.2±3.7210.9±2.86**17.3±4.0912.1±3.20*10.3±2.87**10.2±2.77**10.1±2.86** | 2.22±0.6816.2±3.8620.1±6.2816.0±4.5211.3±2.63*13.0±3.4410.2±2.99*8.67±2.55**10.9±2.63*8.24±2.62* |
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03108971 CN1283288C (zh) | 2003-04-15 | 2003-04-15 | 一种降脂组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 03108971 CN1283288C (zh) | 2003-04-15 | 2003-04-15 | 一种降脂组合物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1537544A CN1537544A (zh) | 2004-10-20 |
CN1283288C true CN1283288C (zh) | 2006-11-08 |
Family
ID=34319168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 03108971 Expired - Lifetime CN1283288C (zh) | 2003-04-15 | 2003-04-15 | 一种降脂组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1283288C (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101850031B (zh) * | 2010-04-23 | 2012-06-27 | 胡庆禧 | 葛根异黄酮胶囊 |
CN104473957B (zh) * | 2014-12-16 | 2016-02-03 | 山东京御堂国药有限公司 | 一种用于降脂的中药单体组合物及其制剂 |
CN104510857B (zh) * | 2014-12-16 | 2016-01-20 | 山东京御堂国药有限公司 | 一种用于降脂的中药有效部位组合物及其制剂 |
CN104474169B (zh) * | 2014-12-16 | 2016-03-30 | 山东京御堂国药有限公司 | 一种葛山降脂颗粒及其制备方法 |
CN104435447B (zh) * | 2014-12-16 | 2016-01-20 | 山东京御堂国药有限公司 | 一种葛山降脂缓释制剂及其制备方法 |
CN104491239B (zh) * | 2014-12-16 | 2016-03-16 | 山东京御堂国药有限公司 | 一种用于降脂的中药组合物及其制剂 |
CN104623136B (zh) * | 2015-01-12 | 2018-08-28 | 李元勋 | 一种辅助降血脂中药保健品当归黄芪降脂颗粒及其制备方法 |
CN105249321A (zh) * | 2015-09-01 | 2016-01-20 | 上海医药工业研究院 | 一种组合物及其制备方法和用途 |
CN105250671A (zh) * | 2015-11-09 | 2016-01-20 | 谢桂斌 | 用于治疗高血脂的药物 |
-
2003
- 2003-04-15 CN CN 03108971 patent/CN1283288C/zh not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CN1537544A (zh) | 2004-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006060951A1 (fr) | Composition pharmaceutique pour le traitement et/ou la prevention de l’hyperlipidemie, procedes de production et utilisation de cette composition | |
CN101804165A (zh) | 一种清肾毒,强健五脏六腑,增强体质延缓衰老的制剂及其制备方法 | |
CN101073606A (zh) | 一种白芍药材的提取分离方法 | |
CN1283288C (zh) | 一种降脂组合物及其制备方法 | |
CN1706463A (zh) | 一种治疗妇科习惯性流产和先兆性流产疾病的药物 | |
CN103372051B (zh) | 一种调节血脂的红曲葛根药物组合及其制备方法 | |
CN103372073A (zh) | 一种调节血脂的红曲山楂药物组合及其制备方法 | |
CN1263503C (zh) | 菖远胶囊及其制备工艺 | |
CN1478508A (zh) | 一种治疗脂肪肝的中药组合物及其制备方法 | |
CN106344804A (zh) | 一种治疗骨折中药组合物及其制备方法 | |
CN1232279C (zh) | 一种降血脂的中药 | |
CN100500183C (zh) | 一种治疗妇女经期疾病的中药合剂的制备方法 | |
CN101698085B (zh) | 一种治疗肝纤维化或肝硬化失代偿早期的药物组合物及制备方法和用途 | |
CN1291709C (zh) | 一种无糖型降脂颗粒及其制备方法 | |
CN1055227C (zh) | 一种治疗男性不育症的药物及制备方法 | |
CN1207044C (zh) | 一种降血脂和抗动脉粥样硬化的药物组合物及其制备方法、用途 | |
CN100409880C (zh) | 一种治疗高脂血症的蒙药保利尔及其制备方法 | |
CN100411642C (zh) | 一种治疗慢性肝炎的药物 | |
CN1883660A (zh) | 降血脂中药及其制备方法 | |
CN1087627C (zh) | 一种治疗糖尿病的药物及其制备方法 | |
CN103372040B (zh) | 一种调节血脂的红曲川芎药物组合及其制备方法 | |
CN101028319B (zh) | 防治冠心病的中药复方制剂及制备方法 | |
CN1814153A (zh) | 一种预防和治疗乳腺癌的药物组合物及其制备方法 | |
CN115487260B (zh) | 一种治疗高胆固醇血症或动脉粥样硬化的中药组合物及其应用 | |
CN103372114B (zh) | 一种调节血脂的红曲泽泻药物组合及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Anhui Academy of Medical Sciences Document name: Notification of acceptance |
|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: SHANDONG LVYIN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: ANHUI PROVINCE MEDICINE SCIENCE INSTITUTE; SANJIU PHARMACEUTICAL CO., LTD. Effective date: 20071123 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20071123 Address after: Linyi hi tech Industrial Development Zone, Shandong, China: 276017 Patentee after: SHANDONG LUYIN PHARMACEUTICAL Address before: No. 15, Yonghong Road, Hefei, Anhui: 230061 Co-patentee before: Sanjiu Medical & Pharmaceutical Co.,Ltd. Patentee before: Anhui Prov. Medical Science Research Inst. |
|
ASS | Succession or assignment of patent right |
Owner name: SHANDONG JINGYUTANG TRADITIONAL CHINESE MEDICINE C Free format text: FORMER OWNER: SHANDONG LUYIN PHARMACEUTICAL CO., LTD. Effective date: 20131204 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 276017 LINYI, SHANDONG PROVINCE TO: 276015 LINYI, SHANDONG PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20131204 Address after: 276015 south section of industry road three, Ma Hu Town, hi tech Development Zone, Shandong, Linyi Patentee after: JINGYUTANG PHARMACEUTICAL CO.,LTD. Address before: 276017 hi tech Industrial Development Zone, Shandong, Linyi Patentee before: SHANDONG LUYIN PHARMACEUTICAL |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20220830 Address after: 276600 west side of the middle section of Gongye Third Road, high tech Zone, Linyi City, Shandong Province Patentee after: Shandong jingyutang Pharmaceutical Co.,Ltd. Address before: 276015 south section of Gongye 3rd road, machanghu Town, high tech Development Zone, Linyi City, Shandong Province Patentee before: JINGYUTANG PHARMACEUTICAL CO.,LTD. |
|
CX01 | Expiry of patent term |
Granted publication date: 20061108 |
|
CX01 | Expiry of patent term |